EA201200501A1 - Композиции и способы лечения бактериальных инфекций, используя цефтаролин - Google Patents

Композиции и способы лечения бактериальных инфекций, используя цефтаролин

Info

Publication number
EA201200501A1
EA201200501A1 EA201200501A EA201200501A EA201200501A1 EA 201200501 A1 EA201200501 A1 EA 201200501A1 EA 201200501 A EA201200501 A EA 201200501A EA 201200501 A EA201200501 A EA 201200501A EA 201200501 A1 EA201200501 A1 EA 201200501A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
ceftarolin
bacterial infections
ceftaroline
Prior art date
Application number
EA201200501A
Other languages
English (en)
Other versions
EA029149B1 (ru
Inventor
Дирк Тай
Джордж Толбот
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201200501A1 publication Critical patent/EA201200501A1/ru
Publication of EA029149B1 publication Critical patent/EA029149B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Изобретение относится к композициям, содержащим цефтаролин или его пролекарство (например, цефтаролин фозамил) и способам лечения бактериальных инфекций, таких как осложненные инфекции кожи и подкожной клетчатки (cSSSI) и внебольничная бактериальная пневмония (САВР) путем введения цефтаролина или его пролекарства (например, цефтаролин фозамила).
EA201200501A 2009-09-21 2010-09-21 Фармацевтические композиции, содержащие цефтаролина фозамил, для лечения бактериальных инфекций EA029149B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14
PCT/US2010/049659 WO2011035305A1 (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Publications (2)

Publication Number Publication Date
EA201200501A1 true EA201200501A1 (ru) 2012-10-30
EA029149B1 EA029149B1 (ru) 2018-02-28

Family

ID=43757152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200501A EA029149B1 (ru) 2009-09-21 2010-09-21 Фармацевтические композиции, содержащие цефтаролина фозамил, для лечения бактериальных инфекций

Country Status (23)

Country Link
US (2) US20110071114A1 (ru)
EP (1) EP2480236A4 (ru)
KR (1) KR20120083344A (ru)
CN (1) CN102781451A (ru)
AU (1) AU2010295269B2 (ru)
BR (1) BR112012006250B1 (ru)
CA (1) CA2774772A1 (ru)
CL (1) CL2012000694A1 (ru)
CO (1) CO6531417A2 (ru)
CR (1) CR20120137A (ru)
CU (1) CU20120048A7 (ru)
DO (1) DOP2012000077A (ru)
EA (1) EA029149B1 (ru)
EC (1) ECSP12011739A (ru)
GT (1) GT201200082A (ru)
HN (1) HN2012000585A (ru)
IL (1) IL218349A0 (ru)
MX (2) MX2012003411A (ru)
NI (1) NI201200045A (ru)
PE (2) PE20121819A1 (ru)
SG (1) SG178936A1 (ru)
WO (1) WO2011035305A1 (ru)
ZA (1) ZA201202924B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2012270051B2 (en) 2011-06-17 2016-12-22 Pfizer Anti-Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
EP2020416A1 (en) * 2000-08-10 2009-02-04 Takeda Pharmaceutical Company Limited Phosphonocephem compound
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
JP4625637B2 (ja) * 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20090082326A1 (en) * 2007-09-21 2009-03-26 Forest Laboratories Holdings Limited Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Also Published As

Publication number Publication date
EP2480236A1 (en) 2012-08-01
BR112012006250B1 (pt) 2021-07-06
ECSP12011739A (es) 2012-05-30
IL218349A0 (en) 2012-04-30
CA2774772A1 (en) 2011-03-24
WO2011035305A1 (en) 2011-03-24
ZA201202924B (en) 2012-12-27
CN102781451A (zh) 2012-11-14
EP2480236A4 (en) 2013-04-17
EA029149B1 (ru) 2018-02-28
CL2012000694A1 (es) 2012-08-31
NI201200045A (es) 2012-11-02
US20150258126A1 (en) 2015-09-17
KR20120083344A (ko) 2012-07-25
MX2012003201A (es) 2012-05-08
US20110071114A1 (en) 2011-03-24
SG178936A1 (en) 2012-04-27
BR112012006250A2 (pt) 2016-05-31
DOP2012000077A (es) 2012-05-31
MX2012003411A (es) 2012-04-30
US9629861B2 (en) 2017-04-25
CO6531417A2 (es) 2012-09-28
HN2012000585A (es) 2015-06-15
AU2010295269B2 (en) 2014-06-05
AU2010295269A1 (en) 2012-04-12
PE20171176A1 (es) 2017-08-22
CU20120048A7 (es) 2012-10-15
CR20120137A (es) 2012-05-28
PE20121819A1 (es) 2013-02-01
GT201200082A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201001639A1 (ru) Композиции и способы их получения и применения
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201190259A1 (ru) Противовирусные соединения
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201390010A1 (ru) Замещенные триазолопиридины
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201201623A1 (ru) Лечение диабета 2 типа
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
EA201490436A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные гомопиперидинилом
EA201590339A1 (ru) Новые антибактериальные соединения
EA201200501A1 (ru) Композиции и способы лечения бактериальных инфекций, используя цефтаролин
IN2015DN02109A (ru)
MX2009009074A (es) Macrolidos basados en eritromicina.
EA201270547A1 (ru) Фармацевтическая композиция
EA201101703A1 (ru) 17β-АЛКИЛ-17α-ОКСИЭСТРАТРИЕНЫ